Now showing items 368-387 of 1090

    • Factors influencing the accuracy of biomechanical breast models. 

      Tanner, C; Schnabel, JA; Hill, DLG; Hawkes, DJ; Leach, MO; Hose, DR (2006-06)
      Recently it has been suggested that finite element methods could be used to predict breast deformations in a number of applications, including comparison of multimodality images, validation of image registration and image ...
    • Failing to Close the Gap Between Evidence and Clinical Practice in Radical Bladder Cancer Radiotherapy. 

      Hafeez, S; Lewis, R; Griffin, C; Hall, E; Huddart, R (2021-01)
    • Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial. 

      James, ND; Spears, MR; Clarke, NW; Dearnaley, DP; Mason, MD; Parker, CC; Ritchie, AWS; Russell, JM; Schiavone, F; Attard, G; de Bono, JS; Birtle, A; Engeler, DS; Elliott, T; Matheson, D; O'Sullivan, J; Pudney, D; Srihari, N; Wallace, J; Barber, J; Syndikus, I; Parmar, MKB; Sydes, MR; STAMPEDE Investigators (2016-03)
      Importance The natural history of patients with newly diagnosed high-risk nonmetastatic (M0) prostate cancer receiving hormone therapy (HT) either alone or with standard-of-care radiotherapy (RT) is not well documented. ...
    • Familial Risks and Mortality in Second Primary Cancers in Melanoma. 

      Chattopadhyay, S; Hemminki, A; Försti, A; Sundquist, K; Sundquist, J; Hemminki, K (2018-10)
      Background: Malignant melanoma (MM) patients are at increasing risk of developing second primary cancers (SPCs). We assessed mortality and risk of SPCs in MM patients with siblings or parents affected with same cancer ...
    • Fast CPU-based Monte Carlo simulation for radiotherapy dose calculation. 

      Ziegenhein, P; Pirner, S; Ph Kamerling, C; Oelfke, U (2015-08)
      Monte-Carlo (MC) simulations are considered to be the most accurate method for calculating dose distributions in radiotherapy. Its clinical application, however, still is limited by the long runtimes conventional implementations ...
    • Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies. 

      Arce Vargas, F; Furness, AJS; Litchfield, K; Joshi, K; Rosenthal, R; Ghorani, E; Solomon, I; Lesko, MH; Ruef, N; Roddie, C; Henry, JY; Spain, L; Ben Aissa, A; Georgiou, A; Wong, YNS; Smith, M; Strauss, D; Hayes, A; Nicol, D; O'Brien, T; Mårtensson, L; Ljungars, A; Teige, I; Frendéus, B; TRACERx Melanoma; TRACERx Renal; TRACERx Lung consortia; Pule, M; Marafioti, T; Gore, M; Larkin, J; Turajlic, S; Swanton, C; Peggs, KS; Quezada, SA (2018-04)
      With the use of a mouse model expressing human Fc-gamma receptors (FcγRs), we demonstrated that antibodies with isotypes equivalent to ipilimumab and tremelimumab mediate intra-tumoral regulatory T (Treg) cell depletion ...
    • FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. 

      Boellaard, R; Delgado-Bolton, R; Oyen, WJG; Giammarile, F; Tatsch, K; Eschner, W; Verzijlbergen, FJ; Barrington, SF; Pike, LC; Weber, WA; Stroobants, S; Delbeke, D; Donohoe, KJ; Holbrook, S; Graham, MM; Testanera, G; Hoekstra, OS; Zijlstra, J; Visser, E; Hoekstra, CJ; Pruim, J; Willemsen, A; Arends, B; Kotzerke, J; Bockisch, A; Beyer, T; Chiti, A; Krause, BJ; European Association of Nuclear Medicine (EANM) (2015-02)
      The purpose of these guidelines is to assist physicians in recommending, performing, interpreting and reporting the results of FDG PET/CT for oncological imaging of adult patients. PET is a quantitative imaging technique ...
    • FDG-PET/CT Limited to the Thorax and Upper Abdomen for Staging and Management of Lung Cancer. 

      Arens, AIJ; Postema, JWA; Schreurs, WMJ; Lafeber, A; Hendrickx, BW; Oyen, WJG; Vogel, WV (2016-01)
      Purpose This study evaluates the diagnostic accuracy of [F-18]-fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) of the chest/upper abdomen compared to the generally performed scan from head ...
    • FDXR is a biomarker of radiation exposure in vivo. 

      O'Brien, G; Cruz-Garcia, L; Majewski, M; Grepl, J; Abend, M; Port, M; Tichý, A; Sirak, I; Malkova, A; Donovan, E; Gothard, L; Boyle, S; Somaiah, N; Ainsbury, E; Ponge, L; Slosarek, K; Miszczyk, L; Widlak, P; Green, E; Patel, N; Kudari, M; Gleeson, F; Vinnikov, V; Starenkiy, V; Artiukh, S; Vasyliev, L; Zaman, A; Badie, C (2018-01-12)
      Previous investigations in gene expression changes in blood after radiation exposure have highlighted its potential to provide biomarkers of exposure. Here, FDXR transcriptional changes in blood were investigated in humans ...
    • Feasibility and applicability of diffusion-weighted and dynamic contrast-enhanced magnetic resonance imaging in routine assessments of children with high-grade gliomas. 

      Carceller, F; Jerome, NP; Miyazaki, K; Collins, DJ; Orton, MR; d'Arcy, JA; Wallace, T; Moreno, L; Pearson, ADJ; Zacharoulis, S; Leach, MO; Marshall, LV; Koh, D-M (2017-02)
      Diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) have been used as imaging biomarkers in adults with high-grade gliomas (HGGs). We incorporated free-breathing DW-MRI and DCE-MRI, ...
    • Feasibility of magnetic resonance guided radiotherapy for the treatment of bladder cancer. 

      Hunt, A; Hanson, I; Dunlop, A; Barnes, H; Bower, L; Chick, J; Cruickshank, C; Hall, E; Herbert, T; Lawes, R; McQuaid, D; McNair, H; Mitchell, A; Mohajer, J; Morgan, T; Oelfke, U; Smith, G; Nill, S; Huddart, R; Hafeez, S (2020-11)
      Whole bladder magnetic resonance image-guided radiotherapy using the 1.5 Telsa MR-linac is feasible. Full online adaptive planning workflow based on the anatomy seen at each fraction was performed. This was delivered within ...
    • Feasibility of MR-guided ultrahypofractionated radiotherapy in 5, 2 or 1 fractions for prostate cancer. 

      Mohajer, J; Dunlop, A; Mitchell, A; Goodwin, E; Nill, S; Oelfke, U; Tree, A (2021-01)
      The drive towards hypofractionated prostate radiotherapy is motivated by a low alpha/beta ratio for prostate cancer (1 to 3 Gy) compared to surrounding organs at risk, implying an improved therapeutic ratio with increasing ...
    • Feasibility of palliating recurrent gynecological tumors with MRGHIFU: comparison of symptom, quality-of-life, and imaging response in intra and extra-pelvic disease. 

      Imseeh, G; Giles, SL; Taylor, A; Brown, MRD; Rivens, I; Gordon-Williams, R; Ter Haar, G; deSouza, NM
      Objective To document longitudinal symptom, quality-of-life and imaging response in patients with recurrent gynecological tumors treated with magnetic resonance guided high intensity focused ultrasound (MRgHIFU), and compare ...
    • Feasibility of using ultrasound for real-time tracking during radiotherapy. 

      Hsu, A; Miller, NR; Evans, PM; Bamber, JC; Webb, S (2005-06)
      This study was designed to examine the feasibility of utilizing transabdominal ultrasound for real-time monitoring of target motion during a radiotherapy fraction. A clinical Acuson 128/XP ultrasound scanner was used to ...
    • Feasibility study of combined dynamic imaging and lymphaticovenous anastomosis surgery for breast cancer-related lymphoedema. 

      Khan, AA; Hernan, I; Adamthwaite, JA; Ramsey, KWD (2019-01)
      Background Breast cancer-related lymphoedema (BCRL) presents a significant healthcare burden and adversely affects quality of life of breast cancer survivors. A prospective feasibility study was performed on lymphaticovenous ...
    • Features and Management of Late Relapse of Nonseminomatous Germ Cell Tumour. 

      Jay, APM; Aldiwani, M; O'Callaghan, ME; Pearce, AK; Huddart, RA; Mayer, E; Reid, AH; Nicol, DL
      Background Late relapse (LR) of nonseminomatous germ cell tumour (NSGCT) is uncommon, with limited data published. LR is defined as relapse occurring after a disease-free interval of 2 yr.Objective To review features of ...
    • Fever of Unknown Origin: the Value of FDG-PET/CT. 

      Kouijzer, IJE; Mulders-Manders, CM; Bleeker-Rovers, CP; Oyen, WJG (2018-03)
      Fever of unknown origin (FUO) is commonly defined as fever higher than 38.3°C on several occasions during at least 3 weeks with uncertain diagnosis after a number of obligatory investigations. The differential diagnosis ...
    • FFPE breast tumour blocks provide reliable sources of both germline and malignant DNA for investigation of genetic determinants of individual tumour responses to treatment. 

      Wilkins, A; Chauhan, R; Rust, A; Pearson, A; Daley, F; Manodoro, F; Fenwick, K; Bliss, J; Yarnold, J; Somaiah, N (2018-08)
      Background Bio-banked formalin-fixed paraffin-embedded (FFPE) tissues provide an excellent opportunity for translational genomic research. Historically matched blood has not always been collected as a source of germline ...
    • Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma. 

      Andtbacka, RHI; Collichio, F; Harrington, KJ; Middleton, MR; Downey, G; Ӧhrling, K; Kaufman, HL (2019-06-06)
      Background Talimogene laherparepvec is an oncolytic immunotherapy approved in the US, Europe, Australia and Switzerland. We report the final planned analysis of OPTiM, a randomized open-label phase III trial in patients ...
    • Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. 

      Fachal, L; Aschard, H; Beesley, J; Barnes, DR; Allen, J; Kar, S; Pooley, KA; Dennis, J; Michailidou, K; Turman, C; Soucy, P; Lemaçon, A; Lush, M; Tyrer, JP; Ghoussaini, M; Moradi Marjaneh, M; Jiang, X; Agata, S; Aittomäki, K; Alonso, MR; Andrulis, IL; Anton-Culver, H; Antonenkova, NN; Arason, A; Arndt, V; Aronson, KJ; Arun, BK; Auber, B; Auer, PL; Azzollini, J; Balmaña, J; Barkardottir, RB; Barrowdale, D; Beeghly-Fadiel, A; Benitez, J; Bermisheva, M; Białkowska, K; Blanco, AM; Blomqvist, C; Blot, W; Bogdanova, NV; Bojesen, SE; Bolla, MK; Bonanni, B; Borg, A; Bosse, K; Brauch, H; Brenner, H; Briceno, I; Brock, IW; Brooks-Wilson, A; Brüning, T; Burwinkel, B; Buys, SS; Cai, Q; Caldés, T; Caligo, MA; Camp, NJ; Campbell, I; Canzian, F; Carroll, JS; Carter, BD; Castelao, JE; Chiquette, J; Christiansen, H; Chung, WK; Claes, KBM; Clarke, CL; GEMO Study Collaborators; EMBRACE Collaborators; Collée, JM; Cornelissen, S; Couch, FJ; Cox, A; Cross, SS; Cybulski, C; Czene, K; Daly, MB; de la Hoya, M; Devilee, P; Diez, O; Ding, YC; Dite, GS; Domchek, SM; Dörk, T; Dos-Santos-Silva, I; Droit, A; Dubois, S; Dumont, M; Duran, M; Durcan, L; Dwek, M; Eccles, DM; Engel, C; Eriksson, M; Evans, DG; Fasching, PA; Fletcher, O; Floris, G; Flyger, H; Foretova, L; Foulkes, WD; Friedman, E; Fritschi, L; Frost, D; Gabrielson, M; Gago-Dominguez, M; Gambino, G; Ganz, PA; Gapstur, SM; Garber, J; García-Sáenz, JA; Gaudet, MM; Georgoulias, V; Giles, GG; Glendon, G; Godwin, AK; Goldberg, MS; Goldgar, DE; González-Neira, A; Tibiletti, MG; Greene, MH; Grip, M; Gronwald, J; Grundy, A; Guénel, P; Hahnen, E; Haiman, CA; Håkansson, N; Hall, P; Hamann, U; Harrington, PA; Hartikainen, JM; Hartman, M; He, W; Healey, CS; Heemskerk-Gerritsen, BAM; Heyworth, J; Hillemanns, P; Hogervorst, FBL; Hollestelle, A; Hooning, MJ; Hopper, JL; Howell, A; Huang, G; Hulick, PJ; Imyanitov, EN; KConFab Investigators; HEBON Investigators; ABCTB Investigators; Isaacs, C; Iwasaki, M; Jager, A; Jakimovska, M; Jakubowska, A; James, PA; Janavicius, R; Jankowitz, RC; John, EM; Johnson, N; Jones, ME; Jukkola-Vuorinen, A; Jung, A; Kaaks, R; Kang, D; Kapoor, PM; Karlan, BY; Keeman, R; Kerin, MJ; Khusnutdinova, E; Kiiski, JI; Kirk, J; Kitahara, CM; Ko, Y-D; Konstantopoulou, I; Kosma, V-M; Koutros, S; Kubelka-Sabit, K; Kwong, A; Kyriacou, K; Laitman, Y; Lambrechts, D; Lee, E; Leslie, G; Lester, J; Lesueur, F; Lindblom, A; Lo, W-Y; Long, J; Lophatananon, A; Loud, JT; Lubiński, J; MacInnis, RJ; Maishman, T; Makalic, E; Mannermaa, A; Manoochehri, M; Manoukian, S; Margolin, S; Martinez, ME; Matsuo, K; Maurer, T; Mavroudis, D; Mayes, R; McGuffog, L; McLean, C; Mebirouk, N; Meindl, A; Miller, A; Miller, N; Montagna, M; Moreno, F; Muir, K; Mulligan, AM; Muñoz-Garzon, VM; Muranen, TA; Narod, SA; Nassir, R; Nathanson, KL; Neuhausen, SL; Nevanlinna, H; Neven, P; Nielsen, FC; Nikitina-Zake, L; Norman, A; Offit, K; Olah, E; Olopade, OI; Olsson, H; Orr, N; Osorio, A; Pankratz, VS; Papp, J; Park, SK; Park-Simon, T-W; Parsons, MT; Paul, J; Pedersen, IS; Peissel, B; Peshkin, B; Peterlongo, P; Peto, J; Plaseska-Karanfilska, D; Prajzendanc, K; Prentice, R; Presneau, N; Prokofyeva, D; Pujana, MA; Pylkäs, K; Radice, P; Ramus, SJ; Rantala, J; Rau-Murthy, R; Rennert, G; Risch, HA; Robson, M; Romero, A; Rossing, M; Saloustros, E; Sánchez-Herrero, E; Sandler, DP; Santamariña, M; Saunders, C; Sawyer, EJ; Scheuner, MT; Schmidt, DF; Schmutzler, RK; Schneeweiss, A; Schoemaker, MJ; Schöttker, B; Schürmann, P; Scott, C; Scott, RJ; Senter, L; Seynaeve, CM; Shah, M; Sharma, P; Shen, C-Y; Shu, X-O; Singer, CF; Slavin, TP; Smichkoska, S; Southey, MC; Spinelli, JJ; Spurdle, AB; Stone, J; Stoppa-Lyonnet, D; Sutter, C; Swerdlow, AJ; Tamimi, RM; Tan, YY; Tapper, WJ; Taylor, JA; Teixeira, MR; Tengström, M; Teo, SH; Terry, MB; Teulé, A; Thomassen, M; Thull, DL; Tischkowitz, M; Toland, AE; Tollenaar, RAEM; Tomlinson, I; Torres, D; Torres-Mejía, G; Troester, MA; Truong, T; Tung, N; Tzardi, M; Ulmer, H-U; Vachon, CM; van Asperen, CJ; van der Kolk, LE; van Rensburg, EJ; Vega, A; Viel, A; Vijai, J; Vogel, MJ; Wang, Q; Wappenschmidt, B; Weinberg, CR; Weitzel, JN; Wendt, C; Wildiers, H; Winqvist, R; Wolk, A; Wu, AH; Yannoukakos, D; Zhang, Y; Zheng, W; Hunter, D; Pharoah, PDP; Chang-Claude, J; García-Closas, M; Schmidt, MK; Milne, RL; Kristensen, VN; French, JD; Edwards, SL; Antoniou, AC; Chenevix-Trench, G; Simard, J; Easton, DF; Kraft, P; Dunning, AM (2020-01-07)
      Genome-wide association studies have identified breast cancer risk variants in over 150 genomic regions, but the mechanisms underlying risk remain largely unknown. These regions were explored by combining association ...